CLINICAL TRIALS PROFILE FOR CLOZAPINE

All Clinical Trials for CLOZAPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000372 ↗	Glycine and D-Cycloserine in Schizophrenia	Withdrawn	Massachusetts General Hospital	Phase 3	1998-03-01	The purpose of this study is to compare the effects of D-cycloserine and glycine for treating negative symptoms (such as loss of interest, loss of energy, loss of warmth, and loss of humor) which occur between phases of positive symptoms (marked by hallucinations, delusions, and thought confusions) in schizophrenics. Clozapine is currently the most effective treatment for negative symptoms of schizophrenia. Two other drugs, D-cycloserine and glycine, are being investigated as new treatments. D-cycloserine improves negative symptoms when added to some drugs, but may worsen these symptoms when given with clozapine. Glycine also improves negative symptoms and may still be able to improve these symptoms when given with clozapine. This study gives either D-cycloserine or glycine (or an inactive placebo) with clozapine to determine which is the best combination. Patients will be assigned to 1 of 3 groups. Group 1 will receive D-cycloserine plus clozapine. Group 2 will receive glycine plus clozapine. Group 3 will receive an inactive placebo plus clozapine. Patients will receive these medications for 8 weeks. Negative symptoms of schizophrenia will be monitored through the Scale for the Assessment of Negative Symptoms, Positive symptoms will be monitored through the Positive and Negative Syndrome Scale, and additionally subjects will complete the Brief Psychiatric Rating Scale and the Global Assessment Scale. An individual may be eligible for this study if he/she is 18 to 65 years old and has been diagnosed with schizophrenia.
NCT00001656 ↗	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders	Completed	National Institute of Mental Health (NIMH)	Phase 4	1997-06-01	The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses. Childhood psychosis is a serious disorder that may have devastating consequences. Effective treatments for the condition are under continual investigation. This study will examine the causes of and offer treatment for childhood psychosis. Participants in this study will undergo psychological tests, blood and urine tests, electroencephalogram (EEG), electrocardiogram (EKG), and magnetic resonance imaging (MRI) scans of the brain for the first 1 to 2 weeks of the study while taking their regular medications. Participants will then be tapered off their medications over 1 to 3 weeks and will continue to stay off medications for an additional 2 days to 3 weeks. During this time, participants will undergo psychiatric, neurological, and cardiac examinations as well as blood tests. After this period without medications, participants will be randomly assigned to receive either clozapine or olanzapine for 8 weeks. An EEG will be performed prior to treatment and after 6 weeks of study medication. Participants who respond well to the study drugs may continue to receive them through their own physician. Participants who do not respond to either clozapine or olanzapine or cannot tolerate their side effects will be treated individually with other drugs until optimum treatment is identified. Regular telephone updates and in person visits to NIH for repeat testing and MRIs will be conducted.
NCT00004826 ↗	Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease	Completed	Memorial Hospital of Rhode Island	N/A	1993-10-01	OBJECTIVES: I. Determine the efficacy and tolerability of clozapine in ameliorating psychosis in patients with idiopathic Parkinson's disease (PD). II. Determine the adverse effects of clozapine on motor function in this patient population. III. Determine the safety of clozapine in psychotic PD patients taking multiple anti-PD medications. IV. Describe the phenomenology of drug induced psychosis in PD.
NCT00014001 ↗	CATIE- Schizophrenia Trial	Completed	National Institute of Mental Health (NIMH)	Phase 4	2000-12-01	The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
NCT00029458 ↗	Clozapine for Treatment-Resistant Mania	Completed	National Institute of Mental Health (NIMH)	Phase 2	2002-01-01	The purpose of this study is to evaluate the safety and effectiveness of clozapine as a treatment for the manic phase of bipolar disorder. A significant proportion of manic patients either do not respond adequately to conventional treatment or cannot tolerate the adverse effects associated with therapeutic doses of these agents. Clozapine may be a safe and effective treatment for mania. However, the efficacy of clozapine as an alternative therapy in treatment-resistant bipolar disorder mania has not been extensively researched. The study will be conducted in three phases. Phase 1 is a screening phase that will take place for 2 to 7 days. Participants will undergo a baseline positron emission tomography (PET) scan of the brain at the end of this period. In Phase 2, participants will be randomly assigned to receive either clozapine or placebo (an inactive pill) for 3 weeks. They may also receive lorazepam for the first 10 days of Phase 2. After 3 weeks, patients treated with clozapine will undergo a second PET scan. During Phase 3, participants who received placebo and did not improve will be offered clozapine for 3 weeks. Those who received clozapine and did not improve will receive other treatment for 3 weeks. At the end of Phase 3, participants who were treated with clozapine will have another PET scan.

Clinical Trial Conditions for CLOZAPINE

Condition Name

Condition Name for CLOZAPINE
Intervention	Trials
Schizophrenia	129
Schizoaffective Disorder	30
Bipolar Disorder	11
Psychotic Disorders	7

Condition MeSH

Condition MeSH for CLOZAPINE
Intervention	Trials
Schizophrenia	148
Psychotic Disorders	52
Disease	25
Mental Disorders	20

Clinical Trial Locations for CLOZAPINE

Trials by Country

Trials by Country for CLOZAPINE
Location	Trials
United States	204
India	22
United Kingdom	14
Canada	14
Spain	14

Trials by US State

Trials by US State for CLOZAPINE
Location	Trials
Massachusetts	22
New York	21
Maryland	17
California	15
Missouri	12

Clinical Trial Progress for CLOZAPINE

Clinical Trial Phase

Clinical Trial Phase for CLOZAPINE
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	1
PHASE2	2

Clinical Trial Status

Clinical Trial Status for CLOZAPINE
Clinical Trial Phase	Trials
Completed	119
Unknown status	18
Recruiting	17

Clinical Trial Sponsors for CLOZAPINE

Sponsor Name

Sponsor Name for CLOZAPINE
Sponsor	Trials
National Institute of Mental Health (NIMH)	23
Dartmouth-Hitchcock Medical Center	10
University of Maryland	9

Sponsor Type

Sponsor Type for CLOZAPINE
Sponsor	Trials
Other	342
Industry	55
NIH	31

Clozapine: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

What is the current clinical-trials footprint for clozapine?

Clozapine is an established therapy with a large historical development record. In the most recent years, publicly visible activity is dominated by (1) incremental clinical work tied to real-world use, safety monitoring, dosing strategies, and special populations, and (2) “new use” or comparative studies rather than broad phase-3 registration programs that would materially shift regulatory status in most jurisdictions.

Practical implication for investors and developers

• Current trial activity is unlikely to re-found the core indication set (treatment-resistant schizophrenia and schizophrenia with recurrent suicidality) in a way that changes the fundamental commercial base, but it can influence label nuance, formulation/titration pathways, and payer access rules.
• The highest-impact commercial items tend to be: (i) programs that reduce monitoring burden, (ii) those that expand access via streamlined protocols, and (iii) comparative or adherence-focused studies that improve operational efficiency in clinics.

Clinical activity categories that show up most often for clozapine in recent cycles

• Safety and monitoring frameworks (ANC surveillance adherence models, risk stratification approaches).
• Dosing initiation and titration (faster titration strategies, inpatient-to-outpatient transitions).
• Special populations (age, comorbidities, adherence challenges).
• Comparative or pragmatic trials (real-world effectiveness against alternative pathways).
• Formulation changes (controlled delivery, tolerability improvements) tied to access and adherence.

No additional registry-level granularity is provided here because the request is for an evidence-grounded “clinical trials update” and market projection, and producing that requires up-to-date, registry-specific trial listings and endpoints.

How large is the clozapine market today and what drives demand?

Clozapine remains a niche but high-value antipsychotic because it is the most consistently effective option for:

• treatment-resistant schizophrenia (TRS)
• schizophrenia with recurrent suicidal behavior

Demand drivers

1. TRS prevalence and prescribing funnel

   • Clozapine demand tracks the number of patients who fail adequate trials of other antipsychotics.
   • A persistent treatment funnel exists even when newer antipsychotics are used first-line, because TRS develops over time and is re-assessed longitudinally.

2. Safety and monitoring access

   • Clozapine’s clinical value is constrained by ANC monitoring requirements.
   • The operational burden affects real-world initiation rates and continuation.

3. Healthcare system processes

   • Countries and payer systems with smoother monitoring infrastructure see higher persistence and lower discontinuation barriers.

4. Treatment adherence

   • Adherence improves with clinic-based monitoring programs and structured titration, and worsens when systems cannot support labs and follow-up.

Market segmentation that matters commercially

• Inpatient initiation versus outpatient stabilization
• Specialty clinics with monitoring capabilities versus general psychiatric settings
• Formulation and administration convenience as a determinant of continuation rates

What does the market projection look like for clozapine?

For an established therapy like clozapine, the forward view depends on whether any of the following occur:

• improved access pathways that reduce monitoring friction
• tolerability improvements that reduce discontinuation
• payer re-coverage of initiation and continuation
• new evidence that expands subgroup use or strengthens guideline placement

Baseline projection framework (directional)

• Stable-to-moderately growing core demand: driven by chronic TRS patient needs and ongoing diagnosis incidence over time.
• Limited upside from “label expansion” in most jurisdictions: because the major indications are already established.
• Upside from operational optimization: if systems reduce monitoring drop-off and discontinuation rates, use intensity can rise even without label changes.

Three scenario lens

1. Conservative: demand flat to low growth; monitoring burden remains a gating factor.
2. Base case: modest growth; incremental process improvements increase initiation and persistence.
3. Upside: faster growth; improved pathways or formulation-led access increase conversion from TRS referral to clozapine continuation.

Quantitative forecasts require a current-year market size and an evidence-backed forecast model with country and channel splits. Those inputs are not included in the prompt, and generating them without registry- and payer-specific data would breach the requirement for hard data.

Which parts of the value chain capture most profit in clozapine?

Clozapine’s economics are shaped by how the market buys and monitors:

• Manufacturing and supply continuity for a drug with strict safety protocols.
• Specialty distribution and clinic workflows that manage ANC scheduling and documentation.
• Payer rules that define initiation criteria and monitoring compliance expectations.
• Switching costs: patients on stable clozapine dosing often do not switch, creating persistence-driven revenue stability.

What is the competitive landscape for clozapine?

Clozapine faces competition primarily from:

• other antipsychotics used before TRS is reached
• augmentation strategies used in partial responders
• in some settings, other “next-step” agents where local formularies restrict clozapine initiation

Key competitive realities

• Clozapine is not typically “substituted” by another class once TRS and suicidality markers point to clozapine.
• Competition is stronger at the earlier lines of therapy and in patients where monitoring access delays initiation.

So what should decision-makers watch next?

Operational endpoints that change commercial outcomes

• Initiation rates in TRS pathways
• Monitoring compliance and time-to-ANC testing
• Discontinuation rates for intolerance versus hematologic safety events
• Persistence and switching rates

Regulatory and policy endpoints

• Any updates to monitoring standards and REMS-like programs by jurisdiction
• Payer policy shifts on coverage criteria
• Guideline updates that change the depth of TRS definition or suicidality criteria

Key Takeaways

• Clozapine demand is structurally linked to TRS and recurrent suicidality, with growth constrained mostly by monitoring access and persistence rather than label uncertainty.
• The current “clinical trials update” landscape is dominated by incremental and pragmatic studies rather than broad, register-changing phase-3 programs.
• Market upside is most likely to come from process improvements that increase initiation and reduce discontinuation, not from a large new indication expansion.

FAQs

1. Why does clozapine market growth depend on monitoring?
   Because ANC testing requirements and workflow burden gate initiation and continuation, which directly affects real-world utilization.

2. Is clozapine expected to face major label expansion soon?
   Broad label expansion is less likely because core indications are already established in most markets; new work more often refines operational use and subgroup protocols.

3. What drives payer coverage decisions for clozapine?
   Coverage usually ties to documented TRS criteria, adherence to monitoring protocols, and clinic capacity to complete required safety surveillance.

4. Which clinical trial types most influence commercial outcomes?
   Studies that change initiation pathways, titration timing, monitoring adherence frameworks, or tolerability and discontinuation patterns.

5. What is the main competitive threat to clozapine?
   Earlier-line prescribing alternatives that delay TRS identification or reduce conversion to clozapine until monitoring and referral pathways are in place.

---

References

[1] U.S. Food and Drug Administration. Clozapine prescribing information (as applicable to approved brand and generic labeling). FDA label documents.
[2] European Medicines Agency. Clozapine product information and safety monitoring requirements. EMA EPAR and annexes.
[3] World Health Organization. Antipsychotic medicines and schizophrenia treatment guidance (latest available updates). WHO guidance documents.